#China #Shanghai #CAR-T therapy #Series A Funding #Vivacta Biotechnology

Vivacta Biotechnology Secures Funding for Revolutionary CAR-T Therapies

Vivacta Biotechnology (Shanghai) Co., Ltd., also known as Vivacta Bio, has announced the successful closure of its Series A and A+ financing rounds, raising over $50 million to further its innovative in vivo CAR-T therapy development. The financing rounds, led by prominent investors such as Loyal Valley Capital and Decheng Capital, aim to enhance clinical trials and global expansion of their groundbreaking treatments designed for cancer and autoimmune disease patients.

A Flourishing Start-Up in Biotechnology

Founded with a mission to transform cancer care, Vivacta Bio stands at the forefront of biotechnological advancements. The recent funding success elevates the company’s ability to continue its pioneering work on in vivo CAR-T therapies—a form of treatment that has shown promising efficacy in early clinical trials for hematological malignancies and autoimmune diseases. Dr. Liu Yarong, the founder and CEO of Vivacta, expressed gratitude for the endorsement from such esteemed investors, highlighting the sustained commitment to innovative healthcare solutions.

The Role of Investors in Expanding Horizons

This funding serves as a testament to the burgeoning interest in the biotech sector, particularly in companies that strive to introduce advanced therapeutic modalities. Notable participants in this investment round include leading firms like OrbiMed, Hankang Capital, and Eisai Innovation Inc., alongside existing shareholders like Qiming Venture Partners and Beijing Shunxi. The diverse backing provides a robust financial foundation for accelerating clinical development and expanding research efforts worldwide.

Focus on Clinical Trials and Regulatory Approvals

A significant portion of the funds will be directed towards the clinical trials of the flagship product, GT801. The therapy has already showcased encouraging safety and efficacy results in preliminary studies, indicating it could provide transformative treatment options for patients facing complex health challenges. The company plans to utilize the new capital to push for regulatory submissions crucial for GT801’s approval, further enhancing its presence in the competitive biotechnology market.

Vivacta recently shared early human data on GT801 during an oral presentation at the American Society of Hematology Annual Meeting in December 2025, spotlighting its potential to alter treatment landscapes. This aspect of communication not only spreads awareness about Vivacta’s innovative direction but also helps in garnering support from industry peers and potential investors.

Bridging the Gap Between Research and Market

The successful closure of funding isn't merely a financial milestone; it is a strategic impetus that enables Vivacta Bio to escalate its ambitions effectively. The management team acknowledges that the funds will also support an expansion of their research and development team, allowing them to explore new avenues and technology enhancements further. This strategy responds to the dynamic pace of advancements within the biotechnology space and helps the firm maintain its competitive edge.

Among the new directors brought on board post-financing is Mr. Xie Ronggang from Loyal Valley Capital, who will lend valuable insight and strategic guidance to the company as it navigates through this pivotal growth period.

About Vivacta and Its Vision

Vivacta emphasizes its commitment to delivering innovative therapies that significantly enhance the quality of life for patients battling cancer and autoimmune diseases. With the company’s next-generation in vivo CAR-T therapy, GT801, they reinforce their role as leaders in avant-garde medical solutions.

The company strongly believes that the collaborative efforts between private equity firms, healthcare investors, and biotechnology innovators will be essential in propelling forward not only Vivacta's mission but also the broader landscape of health solutions.

Conclusion

As the healthcare landscape continues to evolve, Vivacta Biotechnology poses as a critical player, utilizing its latest funding to spearhead initiatives that represent hope and healing for many. The journey of transforming patient care through innovative technology is just beginning, and with robust support, Vivacta is prepared to meet the challenges ahead with resilience and dedication.